We are live on ! Find out more

CUPR

Cuprina Holdings Cayman Ltd

CUPR

Market cap $15.2M

2.17 USD

-0.08

3.56%

At close Updated Oct 6, 4:00 PM EDT

1 day

-3.56%

5 days

5.34%

1 month

-30.45%

3 months

-61.66%

6 months

-31.33%

Year to date

-32.61%

1 year

-74.88%

5 years

-93.46%

10 years

-93.46%

About: Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

Employees: 10

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group

SINGAPORE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or the “Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it has entered into Sale and Purchase Agreements (the “SPAs”) to acquire the entire issued and paid-up share capital of (i) East Coast Podiatry Centre Pte. Ltd. (“ECPC”), which operates East Coast Podiatry Clinic (“ECP”), the leading podiatry-focused chain in Singapore; and (ii) Orchard Clinic Management Pte. Ltd. (“OCM”), which operates Orchard Clinic (“ORC”), a Singapore women's health and wellness clinic (ECPC and OCM together, the “Target Group”), through its direct wholly-owned subsidiary, Cuprina Holdings (BVI) Limited.

Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group

Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it closed the sale of an additional 648,373 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter's over-allotment option granted in connection with the Company's public offering (“PO”, together with such over-allotment closing, the “Offering”), at a public offering price of $1.15 per share, for a total of approximately $745,629 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. As a result, the Company has raised aggregate gross proceeds of approximately $5,716,491, including the previously announced PO gross proceeds of approximately $4,970,862, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering

Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering

SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the closing of its previously announced public offering of an aggregate 4,322,489 Class A Ordinary Shares (“the Offering”) at a price of $1.15 per share (“the Offering Price”) to the public, for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.

Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that an indirectly wholly-owned subsidiary of the Company, Cuprina Pte. Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MEDIFLY Maggots™, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy (MDT).

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements

SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that on June 11, 2026 it has regained compliance with the Nasdaq Capital Markets Listing Requirements.

Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements

Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel (the “Panel”), in response to a staff determination letter (the “Letter”) received on May 27, 2026, from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”). The Letter notified the Company that, due to the Company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), Nasdaq has determined (the “Determination”) that Company's securities will be scheduled for delisting from Nasdaq unless the Company requests an appeal of the Determination to a Panel.

Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

Cuprina Holdings announces 1-for-8 Share Consolidation

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares (“Class A Ordinary Shares”) and Class B ordinary shares (“Class B Ordinary Shares”) (the "Share Consolidation"), effective on or around May 27, 2026.

Cuprina Holdings announces 1-for-8 Share Consolidation

CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cuprina Holdings (Cayman) Limited (“Cuprina” or “the Company”) (NASDAQ: CUPR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm

Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cuprina Holdings (Cayman) Ltd. (NASDAQ: CUPR) resulting from allegations that Cuprina may have issued materially misleading business information to the investing public. So what: If you purchased Cuprina securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a.

Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cuprina Holdings (Cayman) Ltd. (NASDAQ: CUPR) resulting from allegations that Cuprina may have issued materially misleading business information to the investing public. So what: If you purchased Cuprina securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a.

Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

See News Rankings

Price charts implemented using Lightweight Charts™